Table 1.
Patient characteristics
| CP-CML | EUROSKI | TKI (years) (median, range) | Off TKI (years) (median, range) | |
|---|---|---|---|---|
| CML patients, n | 40 | 9 | ||
| Age, years | ||||
| Median | 62 | 65 | ||
| Range | 21–81 | 46–83 | ||
| Sex, n | ||||
| Female | 15 | 5 | ||
| Male | 25 | 4 | ||
| TKI therapy, n | ||||
| Imatinib | 22 | 6 | 6.5 (3.2–7.9) | 2.45 (2.2–2.6) |
| Nilotinib | 14 | 1 | 3.2 | 1.7 |
| Dasatinib | 4 | |||
| Imatinib/dasatinib | 2 | 3.5/1.6; 0.7/4.3 | 1.2; 2.7 | |
| Sokal risk score | ||||
| Low | 15 | |||
| Intermediate | 17 | |||
| High | 8 |
CP-CML chronic phase CML, TKI tyrosine kinase therapy, EURO-SKI multicenter trial estimating the duration of major molecular remission (MMR) in CML patients after discontinuation the TKI